Comparing the current results to its competitors, Incannex Healthcare Inc reported Revenue decrease in the 3 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 18.09 %, recorded in the same quarter.
Incannex Healthcare Inc, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 47.61 %
Incannex Healthcare Inc's Comment on Competition and Industry Peers
The company faces potential competition from major pharmaceutical, biopharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and medical research organizations. Competitors may possess greater financial, manufacturing, marketing, drug development, technical, and human resources. They may obtain FDA or other regulatory approvals for alternative or superior products. Competitors also compete in recruiting and retaining qualified personnel, establishing clinical trial sites, enrolling subjects, and acquiring complementary technologies. Additionally, some competitors have higher name recognition and more extensive collaborative relationships.
May 7, 2024
In a significant step forward in the battle against the opioid epidemic, Incannex Healthcare Inc., a leading cannabinoid and psychedelic medicine biotechnology company, has successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA). The meeting s was to gain FDA approval for the development of CannQuit-O, a potential groundbreaking treatment for Opioid Use Disorder (OUD).Overview of the Press Release:Incannex Healthcare Inc. is pleased to announce the successful completion of its pre-IND meeting with the FDA, marking a crucial milestone in the clinical development of CannQuit-O. With opioid addiction ravaging communities worldwide, the need for effec...
January 17, 2024
Incannex Healthcare Inc. (Nasdaq: IXHL), a pharmaceutical company specializing in developing medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies, has recently received approval from an independent Institutional Review Board (IRB) for the protocol of their Phase 2/3 clinical trial. This trial aims to evaluate the safety and efficacy of their proprietary combination drug candidate, IHL-42X, in patients suffering from obstructive sleep apnea (OSA). With IRB approval, the process of activating clinical trial sites for the RePOSA study can now commence.Obstructive sleep apnea is a common sleep disorder characterized by repetitive episodes of complete or partial upper airway blockage during ...
Fsd Pharma Inc's business model is centered around the development and production of pharmaceutical-grade cannabis products. The company aims to leverage its in-house cultivation facility, research and development capabilities, and strategic partnerships to create innovative cannabis-based therapies for various medical conditions. Fsd Pharma focuses on pursuing licensing and acquisition opportunities to expand its presence in the global cannabis market.
Gh Research Plc's business model revolves around conducting research and development activities in various sectors, likely focused on a specific industry or area of expertise. They may generate revenue through partnerships, collaborations, licensing, or selling their research findings, products, or services to organizations within their targeted market.
The Greater Cannabis Company Inc Share Performance
-23.00%
Over The Past 5 Days
The Greater Cannabis Company Inc
Profile
The Greater Cannabis Company Inc's business model involves the cultivation, processing, and distribution of cannabis products. They aim to offer a wide range of cannabis-related goods to cater to the demands of both medical and recreational users.
Earth Science Tech Inc is a biotechnology company focused on developing and marketing innovative hemp cannabinoid-based products. Their business model revolves around research, development, manufacturing, and distribution of high-quality CBD and nutraceuticals for various industries, including the pharmaceutical and nutrition sectors.
Sources:
Incannex Healthcare Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Incannex Healthcare Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
